UTMD Earnings Date 2026
Utah Medical Products Inc earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$72.25
+0.68% today
Earnings Metrics
EPS (TTM)
$3.96
P/E Ratio
15.4
Revenue Growth
-8.5%
Market Cap
$0.2B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $3.96 | $0.01B | $0.00B |
| Q4 2023 | $4.58 | $0.01B | $0.00B |
Trading Around UTMD Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full UTMD Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is UTMD next earnings date?
UTMD (Utah Medical Products Inc) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is UTMD earnings per share (EPS)?
UTMD's current earnings per share (EPS) is $3.96. With a P/E ratio of 15.4, the market values each dollar of earnings at $15.4.
How often does UTMD report earnings?
Like most publicly traded US companies, UTMD (Utah Medical Products Inc) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does UTMD report earnings?
UTMD typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has UTMD performed in recent earnings?
In the most recent quarter (Q4 2024), UTMD reported EPS of $3.96 on revenue of $0.01B.
What do analysts expect for UTMD earnings?
Analyst expectations for UTMD earnings can vary. The company has shown negative revenue growth of -8.5%. View the full analyst ratings page for detailed expectations.